A multi-drug resistant pathogen reference strain and clinical isolate collection representative of pathogens and resistance mechanisms directly aligned to the PACE first funding call that can be used by the provider to generate antimicrobial susceptibility data across PACE-funded projects and that can be made available to PACE awardees for onward project progression.
Continued expansion and characterisation of the strain and isolate collection to ensure it remains reflective of contemporary and genomically diverse multi-drug resistant and epidemic lineages of target pathogens (~20-30 strains) across E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and S. aureus. This expanded collection will be made available for antimicrobial susceptibility testing (AST) across PACE-funded projects and the wider AMR community.
The Advanced Technologies team at the Medicines Discovery Catapult (MDC) is looking to expand its current advanced microscopy facility to support both our own growing needs and provide the UK SME community access to advanced molecular and cellular imaging.
MDC is aiming purchase a confocal High Content Screening (HCS) instrument based on an automated well-plate inverted microscope, together with confocal and widefield functionalities. It is crucial for the HCS system to be flexible and provide fast and high-resolution imaging of a wide range of experiments.
The instrument should be configured to enable the use of different sample formats (2D and 3D cell models, tissue sections, fixed and live-cell) and experimental types (drug dose responses, live-cell kinetic studies, phenotypic screening, RNA scope), using a large variety of well-plate formats and a wide range of fluorophores. In addition, the HCS instrument must be supplied with a high-end solution for high content image analysis, visualization and handling.